ZA201304139B - Combination - Google Patents

Combination

Info

Publication number
ZA201304139B
ZA201304139B ZA2013/04139A ZA201304139A ZA201304139B ZA 201304139 B ZA201304139 B ZA 201304139B ZA 2013/04139 A ZA2013/04139 A ZA 2013/04139A ZA 201304139 A ZA201304139 A ZA 201304139A ZA 201304139 B ZA201304139 B ZA 201304139B
Authority
ZA
South Africa
Prior art keywords
combination
Prior art date
Application number
ZA2013/04139A
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201304139B publication Critical patent/ZA201304139B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04139A 2011-01-11 2013-06-06 Combination ZA201304139B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (1)

Publication Number Publication Date
ZA201304139B true ZA201304139B (en) 2014-02-26

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04139A ZA201304139B (en) 2011-01-11 2013-06-06 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (https=)
EP (1) EP2663189B1 (https=)
JP (1) JP6100700B2 (https=)
KR (1) KR20140053836A (https=)
CN (1) CN103298345B (https=)
AU (1) AU2012205601B2 (https=)
BR (1) BR112013017722A2 (https=)
CA (1) CA2824201A1 (https=)
EA (1) EA029000B1 (https=)
ES (1) ES2689760T3 (https=)
IL (1) IL227097B (https=)
MX (1) MX356704B (https=)
SG (2) SG191724A1 (https=)
WO (1) WO2012097021A1 (https=)
ZA (1) ZA201304139B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
WO2005095387A1 (en) * 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
EP2708531A1 (en) 2004-10-13 2014-03-19 Pharmacia & Upjohn Company LLC Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
AU2007234379A1 (en) 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
MY149140A (en) 2006-10-13 2013-07-15 Basf Se Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
US20110288142A1 (en) 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
BR112012008274A2 (pt) 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Akt 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
WO2012151413A1 (en) 2011-05-03 2012-11-08 University Of Rochester Methods for treating prostate cancer
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
RS55223B1 (sr) 2011-10-10 2017-02-28 Zach System Postupak za dobijanje 17-supstituisanih steroida
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド

Also Published As

Publication number Publication date
EA201391027A1 (ru) 2014-01-30
EP2663189B1 (en) 2018-07-04
CN103298345A (zh) 2013-09-11
JP2014507412A (ja) 2014-03-27
US20130288984A1 (en) 2013-10-31
WO2012097021A1 (en) 2012-07-19
SG10201600077RA (en) 2016-02-26
MX356704B (es) 2018-06-11
AU2012205601A1 (en) 2013-08-01
US20160022641A1 (en) 2016-01-28
IL227097B (en) 2018-02-28
CN103298345B (zh) 2016-12-14
JP6100700B2 (ja) 2017-03-22
KR20140053836A (ko) 2014-05-08
EA029000B1 (ru) 2018-01-31
EP2663189A4 (en) 2014-06-11
SG191724A1 (en) 2013-08-30
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
BR112013017722A2 (pt) 2016-07-12
US10449226B2 (en) 2019-10-22
CA2824201A1 (en) 2012-07-19
US20120258933A1 (en) 2012-10-11
AU2012205601B2 (en) 2016-03-24
MX2013008074A (es) 2013-08-09
US20170100449A1 (en) 2017-04-13
US20150119337A1 (en) 2015-04-30
US20160375086A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
GB201200073D0 (en) Djml
EP2755962A4 (en) AZAINDAZOLES
GB201307749D0 (en) Colonoscopy-preparation
ZA201304139B (en) Combination
GB201115617D0 (en) Proacess
PL2606715T3 (pl) Kombinacja prasująco-owijająca
GB201121388D0 (en) Safe-pron
GB201104730D0 (en) Therabra
AU5171P (en) Sunparamiho Mandevilla xamabilis
GB201106339D0 (en) Combination
GB201116007D0 (en) Combination
GB201117693D0 (en) Combination
GB201121105D0 (en) Combination
GB201114627D0 (en) Tree-hugger
GB201110319D0 (en) Aerobars
GB201116947D0 (en) Easybrack
GB201116680D0 (en) Doorramp
GB201116533D0 (en) Magno-Rebel
GB201116502D0 (en) Wiglid
GB201118709D0 (en) Thermostud
GB201115563D0 (en) Goalstrike
GB201115387D0 (en) Schoolscene
GB201115381D0 (en) Flood-saver
GB201122299D0 (en) Vaccines-peptides
GB201113677D0 (en) eMeetMe